Scleroderma Market Forecast 2025–2034: Where Businesses Should Invest Next

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Scleroderma Market From 2025 To 2034?

The scleroderma market has experienced robust expansion in recent years. Its size is anticipated to increase from $2.33 billion in 2024 to $2.48 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.6%. The historical surge in this market can be attributed to advances in diagnosis, immunological research, therapeutic developments, awareness and education, and genetic studies.

The scleroderma market is projected to experience substantial growth in the upcoming years. It is forecast to reach $3.24 billion by 2029, achieving a compound annual growth rate (CAGR) of 6.9%. The expansion over the forecast period is driven by developments in biological therapies, precision medicine, stem cell therapies, genomic and biomarker research, and global collaborations. Key trends anticipated during this period include digital health solutions, an increased focus on the microbiome, patient-centric care, regenerative medicine, and initiatives promoting health equity and access.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12615&type=smp

What Are The Drivers Pushing New Developments In The Scleroderma Market?

The increasing occurrence of scleroderma is a key factor propelling the scleroderma market. Scleroderma is defined as a persistent autoimmune condition marked by the uncontrolled proliferation of collagen, a vital protein for skin and tissue structure. This condition develops due to an uncontrolled immune response, which may be initiated by diverse environmental elements. With a growing number of reported cases, the need for enhanced diagnostic methods and effective treatments is increasingly apparent. Therapies for scleroderma play a vital role in disease management and symptom relief through modulating the immune system and reducing susceptibility to environmental hazards. For example, data from June 2022, provided by Karger Publishers, a Switzerland-based publisher of peer-reviewed journals, indicated that 19,000 individuals in the UK and 2.5 million people worldwide were affected by scleroderma. Additionally, an August 2024 research article from the Oxford Academic Press, a UK-based university press associated with the University of Oxford, reported that among 10.1 million individuals in the CPRD, 1,588 cases of systemic sclerosis (SSc) were found, resulting in the diagnosis of 206 cancers, predominantly mucocutaneous (4.5%), lung (2.1%), and breast (1.9%). Consequently, the rising prevalence of scleroderma is a significant growth driver for the scleroderma market.

What Are The Leading Segments Analyzed In The Scleroderma Market?

The sclerodermamarket covered in this report is segmented –

1) By Treatment: Medication; Surgery; Other Treatments

2) By Indication: Systemic Scleroderma; Localized Scleroderma

3) By End User: Hospital; Pharmaceutical Stores; Other End Users

Subsegments:

1) By Medication: Immunosuppressants; Antifibrotic Agents; Vasodilators; Corticosteroids; Pain Relievers

2) By Surgery: Lung Transplantation; Other Surgical Interventions

3) By Other Treatments: Physical Therapy; Occupational Therapy; Lifestyle Modifications; Alternative Therapies

What Key Innovation Trends Are Fueling Advancements In The Scleroderma Market?

A significant and growing trend in the scleroderma market involves the development of new treatments. Leading companies within the scleroderma market are creating innovative drugs aimed at managing symptoms and maintaining their competitive standing. An example of this occurred in April 2022, when Tyr Pharma Inc., a biotherapeutics manufacturer located in the US, secured regulatory approval from the US Food and Drug Administration, a US-based health regulatory body, for efzofitimod, its new drug targeting systemic sclerosis-related interstitial lung disease. This new medication functions as a First-in-class immunomodulator, designed to downregulate and regulate the immune response through the modulation of the neuropilin-2 (NRP2) receptor, thereby alleviating scleroderma symptoms. Furthermore, Efzofitimod targets the identical immune cells implicated in the pathology of SSc-ILD (interstitial lung disease associated with systemic sclerosis) and pulmonary sarcoidosis, which resulted in a reduction of pro-inflammatory markers during a clinical study involving patients with pulmonary sarcoidosis.

Which Key Market Players Are Investing In Expansion And Innovation Of Scleroderma Market?

Major companies operating in the scleroderma market include Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, Abbvie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Cumberland Pharmaceuticals Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals Inc., FibroGen Inc., Argentis Pharmaceuticals LLC, Corbus Pharmaceuticals Holdings Inc., H.A.C. Pharma

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report

Which Region Is Projected To Lead The Scleroderma Market During The Forecast Period?

North America was the largest region in the scleroderma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Scleroderma Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12615&type=smp

Browse Through More Reports Similar to the Global Scleroderma Market 2025, By The Business Research Company

Autoimmune Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Dermatitis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Dermatology Medical Lasers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-medical-lasers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795